Stock Yards Bank & Trust Co. Has $4.53 Million Position in Pfizer Inc. (NYSE:PFE)

Stock Yards Bank & Trust Co. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 22.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 157,415 shares of the biopharmaceutical company’s stock after selling 45,973 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Pfizer were worth $4,532,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the third quarter valued at approximately $30,000. GoalVest Advisory LLC boosted its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer in the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC boosted its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $26.26 on Tuesday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average price is $27.08 and its two-hundred day moving average price is $28.56. Pfizer Inc. has a 1 year low of $25.23 and a 1 year high of $40.37. The firm has a market capitalization of $148.70 billion, a P/E ratio of 72.94, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the firm posted $1.14 earnings per share. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on PFE shares. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.